NHS Trust Fails to Deliver New Drug for Gillotts Student with Duchenne
Gillotts School student Ben Clarke who suffers with Duchenne has been seriously let down by Oxford University Hospital NHS Trust by not being able to prescribe a new drug Givinostat that would slow down his condition.
Ben was referred to a Paediatrician in August 2017 after experiencing frequent falls and head injuries. Following this referral, he was diagnosed with Duchenne Muscular Dystrophy, a condition that progressively weakens muscles, affecting movement and ultimately leading to a loss of independence. Without treatment, children with DMD experience a rapid decline in muscle function, which can result in the need for full-time care and reduced life expectancy.
Local MP for Henley and Thame, Freddie van Mierlo has written to Oxford University Hospitals NHS Trust to formally request an apology. In a meeting with the MP in February, OUH Trust revealed it was ready to roll out an Early Access Programme (EAP) to allow patients to access the new medicine. It later admitted to Alex Clarke, Ben’s father it was not ready and could not commit to a timescale.
Commenting on the Trust’s failure, Freddie van Mierlo MP said “I took the Trust at its word and shared the information with my constituent. To later find out the Trust was not ready and could not provide Ben with the treatment he needs was devastating for the family. It shows a lack of respect towards my constituents.”
Ben’s father, Alex Clarke, said, “As a family, we are doing everything we can to ensure that Ben has the best chance of living a fulfilling life. This drug could slow down the progression of his condition, but we need action now. Every day that passes without access to Givinostat feels like we are running out of time. I urge OUH NHS Trust to follow through on their earlier assurances and get Ben the treatment he urgently needs.“
Other NHS trusts across the country have already begun providing Givinostat under the EAP, and Ben is eligible for the treatment under the programme. Despite this, Oxford University Hospitals NHS Trust has yet to apply for Ben’s inclusion in the programme, citing a lack of medical and pharmacy resources to support its provision.
Ben’s family and the MP are calling on OUH NHS Trust to fulfil their earlier assurances and immediately apply for the Early Access Programme to provide Ben with access to Givinostat. The family remains hopeful that with the right support, Ben can benefit from this life-saving treatment.
Freddie is leading a group of MPs on access to medicines through a new All Party Parliamentary Group (APPG) for access to medicines and medical devices, also demanded urgent action to deliver the new treatment for DMD. Duchenne Muscular Dystrophy is a devastating, progressive, and currently incurable muscle-wasting disease that affects 1 in 3,500 boys worldwide.
Freddie added, “It beggars’ belief that a transformative new medicine is being denied to young boys with Duchenne due to red tape and bureaucracy. The company is providing the medicine for free, meaning OUH only have to find the staff time needed to carry out the consultations needed. Other Trusts in the UK are now providing this medicine and yet boys in Oxfordshire are being let down.”








Leave a Comment
Want to join the discussion?Feel free to contribute!